Literature DB >> 1425738

Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.

D M Johnson1, M E Erwin, M S Barrett, B B Gooding, R N Jones.   

Abstract

RP59500, a semisynthetic pristinamycin combination, and 14 other antimicrobial agents were tested against 108 Legionella strains. Of the ten macrolide, lincosamine and streptogramin agents tested, the new streptogramin RP59500 ranked seventh in order of activity against Legionella pneumophila on the basis of MIC90 results as follows: clarithromycin = 14-OH clarithromycin (MIC90 0.12 mg/l) > roxithromycin > erythromycin = tylosin = virginiamycin > RP59500 (MIC90 1 mg/l) = azithromycin > dirithromycin > clindamycin (MIC90 8 mg/l). Of all 14 drugs tested in this study, rifampicin was the most potent with an MIC90 of 0.008 mg/l. In this retrospective study of Legionella strains (1981-1990 isolates), we observed no trend toward resistance to the agents investigated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425738     DOI: 10.1007/bf01989985

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  The application of molecular and immunologic techniques to study the epidemiology of Legionella pneumophila serogroup 1.

Authors:  M Pfaller; R Hollis; W Johnson; R M Massanari; C Helms; R Wenzel; N Hall; N Moyer; J Joly
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

2.  The activity of imipenem on Legionella pneumophila, with a note on the treatment of two cases.

Authors:  I D Farrell; J Barker; P L Chiodini; J G Hutchison; A M Geddes
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

3.  The effect of charcoal on MICs for Legionella.

Authors:  J Barker; I D Farrell
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

Review 4.  Legionnaires disease: historical perspective.

Authors:  W C Winn
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

5.  Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media.

Authors:  N Bornstein; C Roudier; J Fleurette
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

6.  In vitro activity of azithromycin against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

7.  Effects of tetracyclines on experimental Legionella pneumophila infection in guinea-pigs.

Authors:  S Yoshida; Y Mizuguchi; H Ohta; M Ogawa
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

8.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

9.  Legionnaires' disease associated with a hospital water system: a cluster of 24 nosocomial cases.

Authors:  C M Helms; R M Massanari; R Zeitler; S Streed; M J Gilchrist; N Hall; W J Hausler; J Sywassink; W Johnson; L Wintermeyer; W J Hierholzer
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

10.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

View more
  11 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Antibiotic resistance in common acute respiratory pathogens.

Authors:  P Venkatesan; J A Innes
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

3.  Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.

Authors:  S L Pendland; S J Martin; C Chen; P C Schreckenberger; L H Danziger
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

Review 4.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 5.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 6.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

7.  Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study.

Authors:  S Schönwald; I Kuzman; K Oresković; V Burek; V Skerk; V Car; D Bozinović; J Culig; S Radosević
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

8.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.

Authors:  L A Collins; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.